openPR Logo
Press release

Psychosis Market Detailed Industry Report Analysis 2025-2034

08-22-2025 11:44 AM CET | Health & Medicine

Press release from: Exactitude Consultancy

Psychosis Market

Psychosis Market

Introduction
Psychosis is a severe mental health condition characterized by impaired thoughts, perceptions, and emotions, often presenting in disorders such as schizophrenia, bipolar disorder, and drug-induced psychosis. It significantly affects quality of life and imposes a substantial socioeconomic burden worldwide.
Growing awareness of mental health, increasing prevalence of psychiatric conditions, and the expanding pipeline of innovative drugs and therapies are shaping the psychosis market's future. By leveraging novel treatment approaches such as long-acting injectables, digital therapeutics, and precision psychiatry, the industry is gradually transforming from symptom control toward holistic patient management.

According to Exactitude Consultancy, the global psychosis market was valued at USD 6.12 billion in 2024 and is projected to reach USD 9.56 billion by 2034, growing at a CAGR of 4.6% from 2025 to 2034.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71019

Market Overview
• Market Size (2024): USD 6.12 billion
• Forecast (2034): USD 9.56 billion
• CAGR (2025-2034): 4.6%
• Key Drivers: Increasing prevalence of psychiatric disorders, rising awareness, improved access to mental healthcare, and introduction of advanced long-acting antipsychotics.
• Challenges: Stigma around mental health, high relapse rates, limited innovation in curative therapies, and side effects of existing drugs.
• Leading Players: Johnson & Johnson, Otsuka Pharmaceutical, Eli Lilly, AstraZeneca, Pfizer, Bristol Myers Squibb, Teva, and Sun Pharma.

Market Segmentation
By Product
• First-Generation Antipsychotics
• Second-Generation Antipsychotics
• Long-Acting Injectables (LAIs)
• Adjunctive & Combination Therapies

By Platform
• Oral Medications
• Injectable Medications
• Digital Therapeutics

By Technology
• Conventional Pharmacotherapy
• Precision Psychiatry Tools
• Digital Health Platforms
• AI-Based Diagnostics

By End Use
• Hospitals
• Psychiatric Clinics
• Community Mental Health Centers
• Home Care

By Application
• Schizophrenia
• Bipolar Disorder with Psychotic Features
• Drug-Induced Psychosis
• Delusional Disorders
• Other Psychotic Conditions

Segmentation Summary:
Second-generation antipsychotics dominate due to their broader adoption and lower risk of severe side effects compared to older drugs. However, long-acting injectables (LAIs) are expected to grow fastest, driven by improved patient compliance and reduced relapse rates.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71019/psychosis-market

Regional Analysis
• North America: Largest share, driven by strong healthcare infrastructure, high awareness, and robust reimbursement frameworks.
• Europe: Significant market due to increasing government initiatives on mental health and strong clinical research presence.
• Asia-Pacific: Fastest-growing region; large unmet patient pool, growing urbanization, and improving healthcare accessibility.
• Middle East & Africa: Limited but expanding market; stigma reduction programs and increasing healthcare investments are enabling growth.
• Latin America: Moderate growth led by Brazil and Mexico; rising demand for affordable generics and community-based care initiatives.

Summary:
North America leads in revenue due to advanced psychiatric care systems, but Asia-Pacific is expected to post the highest growth rate through 2034 owing to its large population and rising awareness initiatives.

Market Dynamics
Growth Drivers
• Rising prevalence of schizophrenia and bipolar disorder globally.
• Increased adoption of long-acting injectable therapies for better adherence.
• Expanding mental health awareness campaigns reducing stigma.
• Growing investments in AI-based mental health diagnostics and telepsychiatry.

Challenges
• Persistent stigma surrounding mental illness, especially in low-income regions.
• Side effects associated with current pharmacological treatments.
• Limited innovation in curative therapies-most drugs remain palliative.

Latest Trends
• Adoption of digital therapeutics and mobile apps for monitoring patient behavior.
• Growing emphasis on personalized psychiatry using biomarkers and genetics.
• Development of third-generation antipsychotics with reduced metabolic side effects.
• Integration of telepsychiatry platforms into mainstream healthcare delivery.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71019

Competitor Analysis
Key Players
• Johnson & Johnson
• Otsuka Pharmaceutical Co., Ltd.
• Eli Lilly and Company
• AstraZeneca
• Pfizer Inc.
• Bristol Myers Squibb
• Teva Pharmaceuticals
• Sun Pharmaceutical Industries

Competitive Summary:
The psychosis market is dominated by multinational pharmaceutical leaders with strong antipsychotic portfolios. Strategic collaborations and acquisitions are common, while biotech firms explore innovative therapies, including digital health solutions and targeted molecular approaches.

Conclusion
The psychosis market is set for steady growth, expanding from USD 6.12 billion in 2024 to USD 9.56 billion by 2034 at a CAGR of 4.6%. Rising prevalence, greater mental health awareness, and innovation in long-acting injectables and digital therapeutics are shaping the market's future.
While North America will continue to dominate, Asia-Pacific represents the fastest-growing opportunity, with expanding healthcare access and reduced stigma fueling demand.
Key Takeaway: The psychosis market is poised for transformation, with opportunities for pharmaceutical leaders, digital health innovators, and healthcare providers to redefine psychiatric care over the next decade.

This report is also available in the following languages : Japanese (精神病市場), Korean (정신병 시장), Chinese (精神病市场), French (Marché de la psychose), German (Psychosemarkt), and Italian (Mercato della psicosi), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71019

Our More Reports:

Hearing Aid Devices Market
https://exactitudeconsultancy.com/reports/70776/hearing-aid-devices-market

Powered Surgical Instrument Market
https://exactitudeconsultancy.com/reports/70778/powered-surgical-instrument-market

Autosomal Dominant Polycystic Kidney Disease Market
https://exactitudeconsultancy.com/reports/70780/autosomal-dominant-polycystic-kidney-disease-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.

https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Psychosis Market Detailed Industry Report Analysis 2025-2034 here

News-ID: 4155731 • Views:

More Releases from Exactitude Consultancy

Fuchs' Dystrophy Market Poised to Grow at 8.2% CAGR, Reaching USD 1.15 Billion by 2034
Fuchs' Dystrophy Market Poised to Grow at 8.2% CAGR, Reaching USD 1.15 Billion b …
Introduction Fuchs' endothelial corneal dystrophy (FECD), commonly known as Fuchs' dystrophy, is a progressive eye disease that affects the corneal endothelium-the innermost layer of the cornea responsible for maintaining corneal clarity. The disease leads to corneal swelling, vision distortion, glare, and eventual vision loss. It primarily affects individuals over the age of 50 and is one of the leading indications for corneal transplantation worldwide. While corneal transplant (penetrating keratoplasty or endothelial keratoplasty)
Dry Age-Related Macular Degeneration Market Projected to Grow at 7.9% CAGR, Reaching USD 19.8 Billion by 2034
Dry Age-Related Macular Degeneration Market Projected to Grow at 7.9% CAGR, Reac …
Introduction Dry Age-Related Macular Degeneration (Dry AMD) is a progressive eye disorder that damages the macula, leading to central vision loss. Unlike the wet form of AMD, dry AMD progresses slowly but is more common, accounting for 85-90% of all AMD cases. It is most prevalent in people aged 60 and above, making it a major cause of irreversible vision loss among the elderly. Currently, treatment options for dry AMD are limited
Choroideremia Market Set to Surge at 12.4% CAGR, Reaching USD 210 Million by 2034
Choroideremia Market Set to Surge at 12.4% CAGR, Reaching USD 210 Million by 203 …
Introduction Choroideremia is a rare, inherited X-linked retinal degenerative disease characterized by progressive vision loss, night blindness, and eventual blindness, typically in male patients. Currently, no approved treatment exists to halt or reverse choroideremia progression. However, the emergence of gene therapies, stem cell therapies, and retinal implants is transforming the therapeutic outlook. With rising research investment, orphan drug designations, and growing patient advocacy, the Choroideremia Market is expected to expand significantly
Childhood Atropine for Myopia Progression Market Poised to Grow at 9.9% CAGR, Reaching USD 2.8 Billion by 2034
Childhood Atropine for Myopia Progression Market Poised to Grow at 9.9% CAGR, Re …
Introduction Myopia, or nearsightedness, has reached epidemic proportions worldwide, with prevalence surging particularly in children. Without effective interventions, childhood myopia often progresses to high myopia, significantly raising the risk of retinal detachment, glaucoma, cataracts, and myopic macular degeneration later in life. One of the most promising treatments for slowing myopia progression in children is low-dose atropine therapy. Clinical studies have demonstrated that low concentrations of atropine (0.01% to 0.05%) are effective in

All 5 Releases


More Releases for USD

Chlorella Market Reach USD 465.85 Million USD by 2030
Market Growth Fueled by Increased Adoption of Plant-Based Proteins and Health Supplements Global Chlorella Market size was valued at USD 303.75 Mn. in 2023 and the total Chlorella revenue is expected to grow by 6.3 % from 2024 to 2030, reaching nearly USD 465.85 Mn. . The growth of the market is majorly due to increase in the consumer awareness about health, the inclination towards plant-based food such as chlorella and
Bamboo Clothing Market: USD 1.83B to USD 3.27B by 2030
Bamboo Clothing Market Poised for Robust Growth with Sustainability and Eco-Friendly Trends Driving Demand The global bamboo clothing market is experiencing substantial growth, spurred by a significant shift towards sustainable fashion and eco-friendly materials. As consumers become increasingly conscious of their environmental impact, bamboo fabric-known for its natural, biodegradable properties-is gaining popularity in the fashion industry. This market is expected to continue its upward trajectory, driven by rising demand for eco-conscious
Biometrics Market: "Biometrics: USD 34.3B to USD 112.4B by 2031"
Biometrics Market Market Scope: Key Insights : Biometrics Market size was valued at USD 34.3 billion in 2022 and is poised to grow from USD 39.1 billion in 2023 to USD 112.4 billion by 2031, growing at a CAGR of 14.1% during the forecast period (2024-2031). Discover Your Competitive Edge with a Free Sample Report :https://www.skyquestt.com/sample-request/biometrics-market Access the full 2024 Market report for a comprehensive understanding @https://www.skyquestt.com/report/biometrics-market In-Depth Exploration of the global Biometrics
Advanced (3D/4D) Visualization Systems Market Size, Trends, Growth, Share to sur …
Fatpos Global has carefully studied specific areas, such as application and product type, in the global Advanced (3D/4D) Visualization Systems Market research study. During the predicted period of 2022 to 2032, each kind gives data on sales. The Advanced (3D/4D) Visualization Systems Market analysis examines into the characteristics and financials of the leading participants. As per the analysis research report, the Advanced (3D/4D) Visualization Systems Market to
$100,000,000 USD job contract for travel - $3,000,000 USD referral commission.
Khoja Consultants invites companies, teams or venture capitalists for a $100,000,000 USD contract for travel. The selected company will be providing all accommodations and expenses for a 6-month long business trip around the world. Khoja Consultants expects five-star treatment including close security with private planes, hotels, secured vehicles and helicopters if necessary. More details on the job contract and application are provided at - www.KhojaConsultants.com. There is a $3,000,000
IOT Solutions Market worth USD 553.9 million USD by 2026
"The global IoT solutions market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of cybersecurity as a service market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa." These days many businesses are adopting a market research report